Lung cancer biomarkers and uses thereof
The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
1. A method for detecting protein levels of a set of proteins in a human, the method comprising:
contacting a biological sample from the human with a set of capture reagents, wherein the biological sample is selected from the group consisting of whole blood, plasma, serum and urine, further wherein the capture reagents are aptamers comprising a 5-position pyrimidine modification, further wherein the 5-position pyrimidine modification comprises a substitution with a hydrophobic chemical group selected from the group consisting of benzyl, indole and napthyl, further wherein each capture reagent specifically binds to a different protein of the set of proteins comprising at least C9, MMP-7, ERBB1, IGFBP2, SCFsR and CNDP1; and measuring the level of each protein of the set of proteins based on measurement of the capture reagents.
2. The method of claim 1 , wherein measurement of the protein levels comprises performing an in vitro assay.
3. The method of claim 1 , wherein the biological sample is serum.
4. The method of claim 1 , wherein the human is a smoker.
5. The method of claim 4 , wherein the set of proteins, in addition to C9, MMP-7, ERBB1, IGFBP2, SCFsR and CNDP1, comprises one or more proteins selected from the group consisting of AMPM2; BLC; BMP-1; BTK; Cls; CD30 Ligand; CDK5-p35; CK-MB; Contactin-5; CSK; Cyclophilin A; Endostatin; FGF-17; FYN; GAPDH, liver; HSP 90a; IL-15 Ra; Kallikrein 7; KPCI; LDH-H 1; LRIG3; MEK1; Midkine; MIP-5; PARC; Prothrombin; PTN; RAC1; Renin; sL-Selectin; SELL; TCTP; UBE2N; and Ubiquitin+1.
6. The method of claim 1 , wherein the human has a pulmonary nodule.
7. The method of claim 6 , wherein the set of proteins, in addition to C9, MMP-7, ERBB1, IGFBP2, SCFsR and CNDP1, comprises one or more proteins selected from the group consisting of Apo A-I; b-ECGF; BLC; BMP-1; Cadherin E; Cadherin-6; Calpain I; Catalase; CATC; Cathepsin H; CD30 Ligand; CK-MB; CSK; FGF-17; GAPDH, liver; HMG-1; HSP 90a; HSP 90b; IL-17B; IMB1; KPCI; LGMN; LRIG3; Macrophage mannose receptor; MEK1; METAP1; MK13; NACA; NAGK; Proteinase-3; Prothrombin; RGM-C; SELL; VEGF; and YES.
8. The method of claim 1 , wherein the protein biomarkers, in addition to C9, MMP-7, ERBB1, IGFBP2, SCFsR and CNDP1, comprise LRIG3 and SELL.
9. The method of claim 1 , further comprising measuring the level of the protein PSA-ACT.